CardioGenics (CGNH) 10-Q 24 Mar 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Jan. 31, 2015	Mar. 12, 2015
Document And Entity Information
Entity Registrant Name	CardioGenics Holdings Inc.
Entity Central Index Key	1089029
Document Type	10-Q
Document Period End Date	31-Jan-15
Amendment Flag	FALSE
Current Fiscal Year End Date	-21
Entity Filer Category	Smaller Reporting Company
Entity Common Stock Shares Outstanding		63,312,279
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2015

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Jan. 31, 2015	Oct. 31, 2014
Current Assets
Cash and Cash Equivalents	$84,620	$70,676
Accounts Receivable	202	228
Refundable Taxes Receivable	2,818	2,625
Current Assets, Total	87,640	73,529
Long-Term Assets
Deposits and Prepaid Expenses	40,976	45,576
Property and Equipment, net	40,707	42,693
Patents, net	102,869	108,132
Long Term Assets, Total	184,552	196,401
Total Assets	272,192	269,930
Current Liabilities
Accounts Payable and Accrued Expenses	955,790	1,020,809
Funds Held in Trust for Redemption of Class B Common Shares	4	4
Due to Shareholders	127,535	131,052
Notes Payable, net of debt discount	89,820	71,863
Derivative Liabilities on Notes Payable	647,729	201,260
Total Liabilities	1,820,878	1,424,988
Commitments and Contingencies
Deficiency
Preferred stock; par value $.0001 per share, 50,000,000 shares authorized, none issued
Common stock; par value $.00001 per share; 150,000,000 shares authorized, 58,300,597 and 47,383,379 common shares and 24,176,927 and 24,176,927 exchangeable shares issued and outstanding as of January 31, 2015 and October 31, 2014, respectively	801	692
Additional paid-in capital	47,029,465	46,505,954
Accumulated deficit	-48,698,576	-47,637,746
Accumulated other comprehensive income (loss)	119,624	-23,958
Total Deficiency	-1,548,686	-1,155,058
Total liabilities and deficiency	$272,192	$269,930

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Jan. 31, 2015	Oct. 31, 2014
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, shares issued
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	58,300,597	47,383,379
Common stock, shares outstanding	58,300,597	47,383,379
Exchangeable Shares [Member]
Common stock, shares issued	24,176,927	24,176,927
Common stock, shares outstanding	24,176,927	24,176,927

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended
	Jan. 31, 2015	Jan. 31, 2014
Income Statement [Abstract]
Revenue
Operating Expenses
Depreciation and Amortization of Property and Equipment	1,986	2,743
Amortization of Patent Application Costs	2,379	1,726
General and Administrative	133,611	172,218
Research and Product Development, Net of Investment Tax Credits	67,720	85,483
Total operating expenses	205,696	262,170
Operating Loss	-205,696	-262,170
Other Expenses
Interest Expense and Bank Charges, Net	159,115	111,922
Loss (Gain) on Change in Value of Derivative Liability	652,348	-22,646
Loss on Foreign Exchange Transactions	43,671	56,945
Total other expenses	855,134	146,221
Net Loss	($1,060,830)	($408,391)
Basic and Fully Diluted Net Loss per Common Share	($0.01)	($0.01)
Weighted-average shares of Common Stock outstanding	74,095,036	59,401,454

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) (USD $)	3 Months Ended
	Jan. 31, 2015	Jan. 31, 2014
Statement of Comprehensive Income [Abstract]
Net Loss	($1,060,830)	($408,391)
Other comprehensive income, currency translation adjustments	143,582	104,878
Comprehensive loss	($917,248)	($303,513)

Condensed_Consolidated_Stateme2

Condensed Consolidated Statement of Changes in Deficiency (Unaudited) (USD $)	3 Months Ended
	Jan. 31, 2015
Balance	($1,155,058)
Issuance of common shares on conversion of notes payable November 2014	22,534
Issuance of common shares on conversion of notes payable December 2014	32,260
Issuance of common shares on conversion of notes payable January 2015	83,127
Settlement of derivative value of notes payable on conversion to common shares	385,699
Comprehensive Income (Loss):
Net Loss	-1,060,830
Other Comprehensive Income
Currency Translation Adjustment	143,582
Total Comprehensive Income (Loss)	-917,248
Balance	-1,548,686
Common Stock [Member]
Balance	692
Balance, shares	71,560,306
Issuance of common shares on conversion of notes payable November 2014	6
Issuance of common shares on conversion of notes payable November 2014, shares	589,679
Issuance of common shares on conversion of notes payable December 2014	30
Issuance of common shares on conversion of notes payable December 2014, shares	2,977,637
Issuance of common shares on conversion of notes payable January 2015	73
Issuance of common shares on conversion of notes payable January 2015, shares	7,349,902
Other Comprehensive Income
Balance	801
Balance, shares	82,477,524
Additional Paid-In Capital [Member]
Balance	46,505,954
Issuance of common shares on conversion of notes payable November 2014	22,528
Issuance of common shares on conversion of notes payable December 2014	32,230
Issuance of common shares on conversion of notes payable January 2015	83,054
Settlement of derivative value of notes payable on conversion to common shares	385,699
Other Comprehensive Income
Balance	47,029,465
Accumulated Deficit [Member]
Balance	-47,637,746
Comprehensive Income (Loss):
Net Loss	-1,060,830
Other Comprehensive Income
Total Comprehensive Income (Loss)	-1,060,830
Balance	-48,698,576
Accumulated Other Comprehensive Income (Loss) [Member]
Balance	-23,958
Other Comprehensive Income
Currency Translation Adjustment	143,582
Total Comprehensive Income (Loss)	143,582
Balance	$119,624

Condensed_Consolidated_Stateme3

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	3 Months Ended
	Jan. 31, 2015	Jan. 31, 2014
Cash flows from operating activities:
Net loss	($1,060,830)	($408,391)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,986	2,743
Amortization of Patent Application Costs	2,379	1,726
Loss (Gain) on Change in Value of Derivative Liability	652,348	-22,646
Interest and Discount on Notes Payable	152,781	19,094
Amortization of Discount on Debentures Payable		63,078
Changes in working capital items:
Accounts receivable	26	15
Deposits and Prepaid Expenses	4,600	3,145
Refundable Taxes Receivable	-193	-1,003
Receivable		5,929
Accounts Payable and Accrued Expenses	36,733	119,250
Net cash used in operating activities	-210,170	-217,060
Cash flows from financing activities:
Proceeds from Notes Payable	185,276
Due to Shareholders	-3,517
Issue of Common Shares for Cash		50,000
Net cash provided by financing activities	181,759	50,000
Effects of exchange rate changes on cash	42,355	25,740
Net increase (decrease) in cash and cash equivalents	13,944	-141,320
Cash and cash equivalents, beginning of period	70,676	263,103
Cash and cash equivalents, end of period	$84,620	$121,783

Nature_of_Business

Nature of Business	3 Months Ended
	Jan. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Business	1	Nature of Business
	CardioGenics Inc. (“CardioGenics”) was incorporated on November 20, 1997 in the Province of Ontario, Canada, and carries on the business of development and commercialization of diagnostic test products to the In Vitro Diagnostics testing market. CardioGenics has several test products that are in various stages of development.
	CardioGenics’ business is that of a development-stage company, with a limited history of operations and whose revenues, to date, have been primarily comprised of grant revenue and Scientific Research Tax Credits from government agencies. There can be no assurance that the Company will be successful in obtaining regulatory approval for the marketing of any of the existing or future products that the Company will succeed in developing.

Basis_of_Presentation

Basis of Presentation	3 Months Ended
	Jan. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	2	Basis of Presentation
	In the opinion of management, the unaudited condensed interim consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, necessary to present fairly the condensed interim consolidated financial position of CardioGenics Holdings Inc. and its subsidiaries under generally accepted accounting principles in the United States (“US GAAP”) as of January 31, 2015, their results of operations and cash flows for the three months ended January 31, 2015 and 2014, and the changes in deficiency for the three months ended January 31, 2015. CardioGenics Holdings Inc and its subsidiaries are referred to together herein as the “Company”. Pursuant to rules and regulations of the SEC, certain information and disclosures normally included in financial statements prepared in accordance with US GAAP have been condensed or omitted from these consolidated financial statements unless significant changes have taken place since the end of the most recent fiscal year. Accordingly, these condensed interim consolidated financial statements should be read in conjunction with the consolidated financial statements, notes to consolidated financial statements and the other information in the audited consolidated financial statements of the Company as of October 31, 2014 and 2013 (the “Audited Financial Statements”) included in the Company’s Form 10-K that was previously filed with the SEC on February 12, 2015 and from which the October 31, 2014 consolidated balance sheet was derived.
	The results of the Company’s operations for the three months ended January 31, 2015 are not necessarily indicative of the results of operations to be expected for the full year ending October 31, 2015.
	The accompanying condensed interim consolidated financial statements have been prepared using the accounting principles generally accepted in the United States of America applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business.
	The Company has incurred operating losses and has experienced negative cash flows from operations since inception. The Company has an accumulated deficit at January 31, 2015 of approximately $48.7 million. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs and to allow it to continue as a going concern. The Company has funded its activities to date almost exclusively from debt and equity financings. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.
	The Company will continue to require substantial funds to continue research and development, including preclinical studies and clinical trials of its products, and to commence sales and marketing efforts, if the FDA and other regulatory approvals are obtained. In order to meet its operating cash flow requirements, management’s plans include financing activities such as private placements of its common stock and issuances of convertible debt instruments. Management is also actively pursuing industry collaboration activities including product licensing and specific project financing.
	While the Company believes it will be successful in obtaining the necessary financing to fund its operations and manage costs, there are no assurances that such additional funding will be achieved and that it will succeed in its future operations. The accompanying condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts of liabilities that might be necessary should the Company be unable to continue in existence.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
	Jan. 31, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	3	Summary of Significant Accounting Policies.
	Derivative Instruments
	The Company’s derivative liabilities are related to embedded conversion features of the Notes Payable. For derivative instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in fair value recognized in earnings each reporting period. The Company uses the Black-Scholes model to value the derivative instruments at inception and subsequent valuation dates and the value is re-assessed at the end of each reporting period, in accordance with Accounting Standards Codification (“ASC”) 815. Derivative instrument liabilities are classified in the condensed consolidated balance sheet as current or non-current based on whether or not the net-cash settlement of the derivative instrument could be required within twelve months of the balance sheet date.
	Beneficial Conversion Charge
	The intrinsic value of beneficial conversion features arising from the issuance of convertible debentures with conversion rights that are in-the-money at the commitment date is recorded as debt discount and amortized to interest expense over the term of the debentures. The intrinsic value of a beneficial conversion feature is determined after initially allocating an appropriate portion of the proceeds received from the sale of the debentures to any detachable instruments, such as warrants, included in the sale or exchange based on relative fair values.

Income_Taxes

Income Taxes	3 Months Ended
	Jan. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	4	Income Taxes
	Based on the Company’s evaluation, management has concluded that there are no significant tax positions requiring recognition in the condensed interim consolidated financial statements.
	The Company has incurred losses in Canada since inception, which have generated net operating loss carryforwards for income tax purposes. The net operating loss carryforwards arising from Canadian sources as of January 31, 2015 approximated $6,987,000, which will expire from 2016 through 2035. All fiscal years except 2013 have been assessed.
	A research and development tax credit for 2012 for which the Company received a refund of $81,460 is being refuted by Canadian taxation authorities. The Company is disputing the position taken by the taxation authorities, but has established a reserve against possible repayment.
	Returns required in the US for the years 2008 through 2014 are yet to be filed. As of January 31, 2015, the Company believes it has net operating loss carryforwards from US sources of approximately $44,624,000 available to reduce future Federal taxable income which will expire from 2019 through 2034 once all returns are filed.
	For the three months ended January 31, 2015 and 2014, the Company’s effective tax rate differs from the statutory rate principally due to the net operating losses for which no benefit was recorded.

Notes_Payable

Notes Payable	3 Months Ended
	Jan. 31, 2015
Debt Disclosure [Abstract]
Notes Payable	5	Notes Payable
	On November 19, 2012, the Company entered into an agreement (“Line”) with JMJ Financial (“Lender”) whereby the Company may borrow up to $350,000 from the Lender in increments of $50,000. The Line is subject to an original issue discount of $50,000. Advances under the Line (“Notes”) have a maturity date of one year from the date of the advance. If the advance is repaid within three months the advance is interest free. If not repaid within three months, the advance may not be repaid before maturity and carries interest at 5%. The Lender has the right at any time to convert all or part of the outstanding principal and accrued interest (and any other fees) into shares of fully paid and non-assessable shares of common stock of the Company at a price equal to the lesser of $0.23 and 60% of the lowest trade price in the 25 trading days previous to the conversion. Unless agreed in writing by the parties, at no time will the Lender convert any amount owing under the Line into common stock that would result in the Lender owing more than 4.99% of the common stock outstanding.
	On May 23, 2014, the Company issued promissory notes (the “LG Notes”) to LG Capital Funding, LLC and Adar Bays, LLC (collectively the “Holders”) in the amount of $52,500 each bearing interest at 8% annually due May 23, 2015. The LG Notes and accrued interest may be converted into shares of the Common Stock of the Company at a 42% discount to the lowest closing bid with a 12 day look back. The LG Notes may be prepaid with the following penalties: (i) if the Notes are prepaid within 60 days of the issue date, then at 130% of the face amount plus any accrued interest; and, (ii) if the LG Notes are prepaid after 60 days after the issue date but less than 181 days after the issue date, then at 140% of the face amount plus any accrued interest. The LG Notes may not be prepaid after the 180th day after issue.
	On November 12, 2014, the Company received $50,000 from Chicago Ventures in exchange for a note payable bearing interest at 10% due in one year, convertible into shares in the Company’s common stock at a 40% discount from the lowest closing price of the common shares over the prior 15 days.
	On November 20, 2014, the Company reached a settlement with IBC Funds, LLC (“IBC”) whereby IBC agreed to pay $78,026 of the Company’s debts in exchange for the right to purchase shares in the Company’s common stock at a 40% discount from the lowest closing price of the common shares over the prior 15 days.
	On December 15, 2014, the Company received $52,500 from LG Capital in exchange for a note payable bearing interest at 8% due in one year, convertible into shares in the Company’s common stock at a 42% discount from the lowest closing price of the common shares over the prior 15 days.
	A summary of the Notes Payable at January 31, 2015 and October 31, 2014 follows:
			31-Jan-15			31-Oct-14
	Convertible Note Payable, due February 20, 2015		$	-		$	12,529
	Convertible Notes Payable, due May 23, 2015			41,200			105,000
	Convertible Note Payable, due June 23, 2015			40,000			40,000
	Convertible Note Payable, due October 22, 2015			35,000			35,000
	Convertible Note Payable, due November 12, 2015			50,000			-
	Convertible IBC Funds, LLC Payable, due November 21, 2015			16,421			-
	Convertible Note Payable, due December 15, 2015			52,500			-
	Debt Discount - value attributable to conversion feature attached to notes, net of accumulated amortization of $89,820 and $71,863			(145,301	)		(120,666	)
	Total			89,820			71,863
	Less: Current portion			89,820			71,863
	Total Long-term portion		$	-		$	-
	As described in further detail in Note 6, “Derivative Liabilities”, the Company determines the fair value of the embedded derivatives and records them as a discount to the Notes and as a derivative liability. Upon conversion of the Notes to Common Stock, any remaining unamortized discount is charged to financing expense.

Derivative_Liabilities

Derivative Liabilities	3 Months Ended
	Jan. 31, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Liabilities	6	Derivative Liabilities
	Convertible notes-embedded conversion features:
	The Notes meet the definition of a hybrid instrument, as defined in ASC 815. The hybrid instrument is comprised of a i) a debt instrument, as the host contract and ii) an option to convert the debentures into common stock of the Company, as an embedded derivative. The embedded derivatives derive their value based on the underlying fair value of the Company’s common stock. The embedded derivatives are not clearly and closely related to the underlying host debt instrument since the economic characteristics and risk associated with these derivatives are based on the common stock fair value.
	The Company determines the fair value of the embedded derivatives and records them as a discount to the Notes and a derivative liability. The Company has recognized a derivative liability of $647,729 at January 31, 2015. Accordingly, changes in the fair value of the embedded derivative are immediately recognized in earnings and classified as a gain or loss on the embedded derivative financial instrument in the accompanying condensed consolidated statements of operations. The Company incurred a loss of $652,348 in the fair value for the three months ended January 31, 2015.
	The Company estimated the fair value of the embedded derivatives using a Black Scholes model with the following assumptions: conversion price $0.024 + $0.026 per share according to the agreements; risk free interest rate of .11%; expected life of 1 year; expected dividend of zero; a volatility factor of 223% to 342%, as of January 31, 2015. The expected lives of the instruments are equal to the contractual term of the conversion option. The expected volatility is based on the historical price volatility of the Company’s common stock. The risk-free interest rate represents the U.S. Treasury constant maturities rate for the expected life of the related conversion option. The dividend yield represents anticipated cash dividends to be paid over the expected life of the conversion option.

Fair_Value_Measurements

Fair Value Measurements	3 Months Ended
	Jan. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurements	7	Fair Value Measurements
	As defined by the ASC, fair value measurements and disclosures establish a hierarchy that prioritizes fair value measurements based on the type of inputs used for the various valuation techniques (market approach, income approach and cost approach). The levels of hierarchy are described below:
		●	Level 1: Observable inputs such as quoted market prices in active markets for identical assets or liabilities.
		●	Level 2: Inputs other than quoted market prices that are observable for the asset or liability, either directly or indirectly; these include quoted prices for similar assets or liabilities in active markets, such as interest rates and yield curves that are observable at commonly-quoted intervals.
		●	Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions, as there is little, if any, related market activity.
	The following table summarizes the financial liabilities measured at fair value on a recurring basis as of January 31, 2015, segregated by the level of the valuation inputs within the fair value hierarchy utilized to measure fair value:
			Quoted Prices in											Total Increase (Reduction)
			Active Markets for			Significant Other				Significant				in Fair Value
	Balance Sheet		Identical Assets or			Observable Inputs				Unobservable		31-Jan-15		Recorded at
	Location		Liabilities (Level 1)			(Level 2)				Inputs (Level 3)		Total		31-Jan-15
	Liabilities:
	Derivative liability - Notes		$	-		$	-			$	647,729	$	647,729	$	652,348
	The table below sets forth a summary of changes in the fair value of the Company’s Level 3 financial liability, or derivative liabilities related to the senior secured convertible notes and warrants, for the three months ended January 31, 2015 and 2014.
			2015				2014
	Balance at beginning of period		$	201,260			$	99,702
	Additions to derivative instruments			179,820				-
	Change in fair value of derivative liabilities			652,348				(22,646	)
	Settlements			(385,699	)			(18,400	)
	Balance at end of period		$	647,729			$	58,656

Debentures_Payable

Debentures Payable	3 Months Ended
	Jan. 31, 2015
Debt Disclosure [Abstract]
Debentures Payable	8	Debentures Payable
	In February 2013, shareholder loans were converted on a dollar-for-dollar basis for Series A Convertible Debenture Units (the “A Units”). Each A Unit includes a debenture having a term of three years, bearing interest at 10%, and a warrant having a term of three years. The debentures are convertible at any time into common shares of the Company’s stock at a price of $0.25 per share. The warrants entitle the holder to purchase 2 times the number of common shares of the Company’s stock allowed in conjunction with the debentures at a price of $0.25 per share at any time up to three years.
	In May and June 2013, the Company sold Series B Convertible Debenture Units (the “B Units”). Each B Unit includes a debenture having a term of three years, bearing interest at 10%, and a warrant having a term of three years. The debentures are convertible at any time into common shares of the Company’s stock at a price of $0.25 per share. The warrants entitle the holder to purchase 1.5 times the number of common shares of the Company’s stock allowed in conjunction with the debentures at a price of $0.15 at any time up to three years.
	On September 17, 2004, the Series A and Series B Convertible Debentures plus accrued interest were converted to 9,427,576 common shares.

StockBased_Compensation

Stock-Based Compensation	3 Months Ended
	Jan. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	9	Stock Based Compensation
	Stock-based employee compensation related to stock options for the three months ended January 31, 2015 and 2014 amounted to $-0-.
	The following is a summary of the common stock options granted, forfeited or expired and exercised under the Plan:
					Weighted
					Average
					Exercise
			Options		Price
	Outstanding – October 31, 2013			30,000	$	0.9
	Granted			▬		▬
	Forfeited/Expired			▬		▬
	Exercised			▬		▬
	Outstanding – October 31, 2014			30,000	$	0.9
	Granted			▬		▬
	Forfeited/Expired			▬		▬
	Exercised			▬		▬
	Outstanding – January 31, 2015			30,000	$	0.9
	Options typically vest immediately at the date of grant. As such, the Company does not have any unvested options or unrecognized compensation expense at January 31, 2015.

Warrants

Warrants	3 Months Ended
	Jan. 31, 2015
Equity [Abstract]
Warrants	10	Warrants
	Outstanding warrants are as follows:
			31-Jan-15		31-Oct-14
	Issued to Flow Capital Advisors Inc. on settlement of lawsuit in August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $0.30 per common share up to and including August 23, 2016			250,000		250,000
	Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $0.50 per common share up to and including August 23, 2016			250,000		250,000
	Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $0.75 per common share up to and including August 23, 2016			500,000		500,000
	Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $1.00 per common share up to and including August 23, 2016			500,000		500,000
	Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $0.75 per common share up to and including August 23, 2016			500,000		500,000
	Issued to debenture holders February 2013 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.25 per common share up to and including February 27, 2016			600,000		600,000
	Issued to debenture holders May 2013 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.15 per common share up to and including June 3, 2016			750,000		750,000
	Issued to debenture holders June 2013 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.15 per common share up to and including June 3, 2016			232,500		232,500
	Issued to consultants in August 5, 2013 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.15 per common share up to and including August 4, 2023			2,500,000		2,500,000
	Issued to consultants in August 5, 2013 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.10 per common share up to and including August 4, 2023			1,500,000		1,500,000
	Issued to consultant in September 3, 2013 entitling the holder to purchase 1 common share in the Company at an exercise price of $0.50 per common share up to and including July 31, 2018			500,000		500,000
	Issued to shareholder October 29, 2013 entitling the holder to purchase 1 common share in the Company at an exercise price of $0.15 per common share up to and including October 29, 2016			250,000		250,000
	Issued to shareholder November 7, 2013 entitling the holder to purchase 1 common share in the Company at an exercise price of $0.15 per common share up to and including November 7, 2016			125,000		125,000
	Total Warrants outstanding			8,457,500		8,457,500

Issuance_of_Common_Stock

Issuance of Common Stock	3 Months Ended
	Jan. 31, 2015
Equity [Abstract]
Issuance of Common Stock	11	Issuance of Common Stock
	On January 17, 2013, the Company’s articles of incorporation were amended to increase the total number of common and preferred shares authorized for issuance from 65,000,000 shares to 150,000,000 shares and 5,000,000 shares to 50,000,000 respectively, par value $0.00001 per share.
	During the three months ended January 31, 2015, the Company issued the following common shares:
	Issued on conversion of notes payable		10,917,218

Net_Loss_per_Share

Net Loss per Share	3 Months Ended
	Jan. 31, 2015
Earnings Per Share [Abstract]
Net Loss per Share	12	Net Loss per Share
	The following table sets forth the computation of weighted-average shares outstanding for calculating basic and diluted loss per share:
			Three Months Ended
			January 31,
			2015		2014
	Weighted-average shares - basic			74,095,036		59,401,454
	Effect of dilutive securities			▬		▬
	Weighted-average shares - diluted			74,095,036		59,401,454
	Basic and diluted loss per share for the three months ended January 31, 2015 and 2014 have been computed by dividing the net loss available to common stockholders for each respective period by the weighted average shares outstanding during that period. All outstanding options, warrants and shares to be issued upon the exercise of the outstanding options and warrants representing 29,074,285 and 12,725,418 incremental shares, respectively, have been excluded from the three months ended January 31, 2015 and 2014 computations of diluted earnings per share as they are antidilutive given the net losses generated.

Supplemental_Disclosure_of_Cas

Supplemental Disclosure of Cash Flow Information	3 Months Ended
	Jan. 31, 2015
Supplemental Cash Flow Elements [Abstract]
Supplemental Disclosure of Cash Flow Information	13	Supplemental Disclosure of Cash Flow Information
			For the Three Months Ended
			January 31,
			2015		2014
	Cash paid during the period for:
	Interest		$	6,334	$	3,856
	Income taxes		$	▬	$	▬
	Non-cash financing activities:
	Conversion of notes payable		$	137,921	$	12,066
	Settlement of derivative liability		$	385,699	$	18,400
	Issuance of shares on settlement of suit		$	▬	$	189,000

Subsequent_Events

Subsequent Events	3 Months Ended
	Jan. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	14	Subsequent Events
		a.	In February 2015, an officer of the Company exchanged $22,856 in shareholder’s loans for 227,273 common shares of the Company.
		b.	In February 2015, the Company issued 100,000 common shares of the Company to a consultant in exchange for services rendered.
		c.	In February 2015, $10,561 in principal amount of LG Capital notes payable were converted to 1,456,703 common shares of the Company.
		d.	In February 2015, $21,700 in principal amount of Adar Bays notes payable were converted to 3,227,706 common shares of the Company.
		e.	In March 2015, the Company received $55,250 from Actus Private Equity in exchange for a note payable bearing interest at 8% due in one year, convertible into shares in the Company’s common stock at a 40% discount from the lowest closing price of the common shares over the prior 10 days.
		f.	In March 2015, $10,072 in principal amount of LG Capital notes payable were converted to 1,039,913 common shares of the Company.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Jan. 31, 2015
Accounting Policies [Abstract]
Derivative Instruments	Derivative Instruments
	The Company’s derivative liabilities are related to embedded conversion features of the Notes Payable. For derivative instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in fair value recognized in earnings each reporting period. The Company uses the Black-Scholes model to value the derivative instruments at inception and subsequent valuation dates and the value is re-assessed at the end of each reporting period, in accordance with Accounting Standards Codification (“ASC”) 815. Derivative instrument liabilities are classified in the condensed consolidated balance sheet as current or non-current based on whether or not the net-cash settlement of the derivative instrument could be required within twelve months of the balance sheet date.
Beneficial Conversion Charge	Beneficial Conversion Charge
	The intrinsic value of beneficial conversion features arising from the issuance of convertible debentures with conversion rights that are in-the-money at the commitment date is recorded as debt discount and amortized to interest expense over the term of the debentures. The intrinsic value of a beneficial conversion feature is determined after initially allocating an appropriate portion of the proceeds received from the sale of the debentures to any detachable instruments, such as warrants, included in the sale or exchange based on relative fair values.

Notes_Payable_Tables

Notes Payable (Tables)	3 Months Ended
	Jan. 31, 2015
Debt Disclosure [Abstract]
Summary of Notes Payable	A summary of the Notes Payable at January 31, 2015 and October 31, 2014 follows:
		31-Jan-15			31-Oct-14
	Convertible Note Payable, due February 20, 2015	$	-		$	12,529
	Convertible Notes Payable, due May 23, 2015		41,200			105,000
	Convertible Note Payable, due June 23, 2015		40,000			40,000
	Convertible Note Payable, due October 22, 2015		35,000			35,000
	Convertible Note Payable, due November 12, 2015		50,000			-
	Convertible IBC Funds, LLC Payable, due November 21, 2015		16,421			-
	Convertible Note Payable, due December 15, 2015		52,500			-
	Debt Discount - value attributable to conversion feature attached to notes, net of accumulated amortization of $89,820 and $71,863		(145,301	)		(120,666	)
	Total		89,820			71,863
	Less: Current portion		89,820			71,863
	Total Long-term portion	$	-		$	-

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	3 Months Ended
	Jan. 31, 2015
Fair Value Disclosures [Abstract]
Schedule of Fair Value of Liabilities Measured on Recurring Basis	The following table summarizes the financial liabilities measured at fair value on a recurring basis as of January 31, 2015, segregated by the level of the valuation inputs within the fair value hierarchy utilized to measure fair value:
		Quoted Prices in											Total Increase (Reduction)
		Active Markets for			Significant Other				Significant				in Fair Value
	Balance Sheet	Identical Assets or			Observable Inputs				Unobservable		31-Jan-15		Recorded at
	Location	Liabilities (Level 1)			(Level 2)				Inputs (Level 3)		Total		31-Jan-15
	Liabilities:
	Derivative liability - Notes	$	-		$	-			$	647,729	$	647,729	$	652,348
Schedule of Changes in Fair Value of Financial Liabilities or Derivative Liabilities	The table below sets forth a summary of changes in the fair value of the Company’s Level 3 financial liability, or derivative liabilities related to the senior secured convertible notes and warrants, for the three months ended January 31, 2015 and 2014.
		2015				2014
	Balance at beginning of period	$	201,260			$	99,702
	Additions to derivative instruments		179,820				-
	Change in fair value of derivative liabilities		652,348				(22,646	)
	Settlements		(385,699	)			(18,400	)
	Balance at end of period	$	647,729			$	58,656

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	3 Months Ended
	Jan. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity	The following is a summary of the common stock options granted, forfeited or expired and exercised under the Plan:
				Weighted
				Average
				Exercise
		Options		Price
	Outstanding – October 31, 2013		30,000	$	0.9
	Granted		▬		▬
	Forfeited/Expired		▬		▬
	Exercised		▬		▬
	Outstanding – October 31, 2014		30,000	$	0.9
	Granted		▬		▬
	Forfeited/Expired		▬		▬
	Exercised		▬		▬
	Outstanding – January 31, 2015		30,000	$	0.9

Warrants_Tables

Warrants (Tables)	3 Months Ended
	Jan. 31, 2015
Equity [Abstract]
Schedule of Warrants Outstanding	Outstanding warrants are as follows:
		31-Jan-15		31-Oct-14
	Issued to Flow Capital Advisors Inc. on settlement of lawsuit in August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $0.30 per common share up to and including August 23, 2016		250,000		250,000
	Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $0.50 per common share up to and including August 23, 2016		250,000		250,000
	Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $0.75 per common share up to and including August 23, 2016		500,000		500,000
	Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $1.00 per common share up to and including August 23, 2016		500,000		500,000
	Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $0.75 per common share up to and including August 23, 2016		500,000		500,000
	Issued to debenture holders February 2013 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.25 per common share up to and including February 27, 2016		600,000		600,000
	Issued to debenture holders May 2013 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.15 per common share up to and including June 3, 2016		750,000		750,000
	Issued to debenture holders June 2013 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.15 per common share up to and including June 3, 2016		232,500		232,500
	Issued to consultants in August 5, 2013 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.15 per common share up to and including August 4, 2023		2,500,000		2,500,000
	Issued to consultants in August 5, 2013 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.10 per common share up to and including August 4, 2023		1,500,000		1,500,000
	Issued to consultant in September 3, 2013 entitling the holder to purchase 1 common share in the Company at an exercise price of $0.50 per common share up to and including July 31, 2018		500,000		500,000
	Issued to shareholder October 29, 2013 entitling the holder to purchase 1 common share in the Company at an exercise price of $0.15 per common share up to and including October 29, 2016		250,000		250,000
	Issued to shareholder November 7, 2013 entitling the holder to purchase 1 common share in the Company at an exercise price of $0.15 per common share up to and including November 7, 2016		125,000		125,000
	Total Warrants outstanding		8,457,500		8,457,500

Issuance_of_Common_Stock_Table

Issuance of Common Stock (Tables)	3 Months Ended
	Jan. 31, 2015
Equity [Abstract]
Schedule of Common Stock Issue	During the three months ended January 31, 2015, the Company issued the following common shares:
	Issued on conversion of notes payable	10,917,218

Net_Loss_per_Share_Tables

Net Loss per Share (Tables)	3 Months Ended
	Jan. 31, 2015
Earnings Per Share [Abstract]
Computation of Weighted Average Shares Outstanding for Calculating Basic and Diluted Earnings Per Share	The following table sets forth the computation of weighted-average shares outstanding for calculating basic and diluted loss per share:
		Three Months Ended
		January 31,
		2015		2014
	Weighted-average shares - basic		74,095,036		59,401,454
	Effect of dilutive securities		▬		▬
	Weighted-average shares - diluted		74,095,036		59,401,454

Supplemental_Disclosure_of_Cas1

Supplemental Disclosure of Cash Flow Information (Tables)	3 Months Ended
	Jan. 31, 2015
Supplemental Cash Flow Information [Abstract]
Cash Flow Supplemental Disclosures		For the Three Months Ended
		January 31,
		2015		2014
	Cash paid during the period for:
	Interest	$	6,334	$	3,856
	Income taxes	$	▬	$	▬
	Non-cash financing activities:
	Conversion of notes payable	$	137,921	$	12,066
	Settlement of derivative liability	$	385,699	$	18,400
	Issuance of shares on settlement of suit	$	▬	$	189,000

Basis_of_Presentation_Details_

Basis of Presentation (Details Narrative) (USD $)	Jan. 31, 2015	Oct. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$48,698,576	$47,637,746

Income_Taxes_Details_Narrative

Income Taxes (Details Narrative) (USD $)	3 Months Ended		12 Months Ended
	Jan. 31, 2015	Jan. 31, 2014	Oct. 31, 2012
Operating Loss Carryforwards [Line Items]
Income tax benefits
Canadian Taxation Authorities[Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carry forwards	6,987,000
Operating loss carry forwards expiration period	from 2016 through 2035
Research and development tax credit received refund amount			81,460
U S [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carry forwards	$44,624,000
Operating loss carry forwards expiration period	from 2019 through 2034
Federal taxable income returns for years	2008 through 2014

Notes_Payable_Details_Narrativ

Notes Payable (Details Narrative) (USD $)	0 Months Ended	3 Months Ended		0 Months Ended
	Nov. 19, 2012	Jan. 31, 2015	Jan. 31, 2014	23-May-14	Nov. 12, 2014	Nov. 20, 2014	Dec. 15, 2014
NotesPayableLineItems [Line Items]
Line of credit facility, maximum borrowing capacity	$350,000
Line of credit facility original issue discount	50,000
Line of credit facility, interest rate during period	5.00%
Lenders right relating to notes payable description	The Lender has the right at any time to convert all or part of the outstanding principal and accrued interest (and any other fees) into shares of fully paid and non-assessable shares of common stock of the Company at a price equal to the lesser of $0.23 and 60% of the lowest trade price in the 25 trading days previous to the conversion.
Conversion price per share	$0.23
Percentage of lowest trading price of debt instrument on before conversion	60.00%
Line of credit facility common stock outstanding percentage	4.99%
Debt in exchange to purchase common stock shares		137,921	12,066
LG Capital Funding, LLC and Adar Bays, LLC [Member]
NotesPayableLineItems [Line Items]
Proceeds from issuance of promissory note				52,500
Debt instruments interest rate				8.00%
Debt instrument maturity Date				23-May-15
LG Capital Funding [Member]
NotesPayableLineItems [Line Items]
Percentage of debt converted into stock discount				42.00%
Debt penalties for issued date below 60 days				130.00%
Debt penalties for issued date After 60 days				140.00%
Chicago Ventures [Member]
NotesPayableLineItems [Line Items]
Debt instruments interest rate					10.00%
Percentage of debt converted into stock discount					40.00%
Convertible note payable					50,000
Debt term					15 days
IBC Funds, LLC [Member]
NotesPayableLineItems [Line Items]
Percentage of debt converted into stock discount						40.00%
Debt term						15 days
Debt in exchange to purchase common stock shares						78,026
LG Capital Funding, LLC [Member]
NotesPayableLineItems [Line Items]
Debt instruments interest rate							8.00%
Percentage of debt converted into stock discount							42.00%
Convertible note payable							$52,500
Debt term							15 days

Notes_Payable_Summary_of_Notes

Notes Payable - Summary of Notes Payable (Details) (USD $)	Jan. 31, 2015	Oct. 31, 2014
Short-term Debt [Line Items]
Debt Discount - value attributable to conversion feature attached to notes, net of accumulated amortization of $89,820 and $71,863	($145,301)	($120,666)
Total	89,820	71,863
Less: Current portion	89,820	71,863
Total Long-term portion
Convertible Note Payable, Due February 20, 2015 [Member]
Short-term Debt [Line Items]
Convertible Note Payable		12,529
Convertible Notes Payable, Due May 23, 2015 [Member]
Short-term Debt [Line Items]
Convertible Note Payable	41,200	105,000
Convertible Note Payable, Due June 23, 2015 [Member]
Short-term Debt [Line Items]
Convertible Note Payable	40,000	40,000
Convertible Note Payable, Due October 22, 2015 [Member]
Short-term Debt [Line Items]
Convertible Note Payable	35,000	35,000
Convertible Note Payable, due November 12, 2015 [Member]
Short-term Debt [Line Items]
Convertible Note Payable	50,000
Convertible IBC Funds, LLC Payable, due November 21, 2015 [Member]
Short-term Debt [Line Items]
Convertible Note Payable	16,421
Convertible Note Payable, due December 15, 2015 [Member]
Short-term Debt [Line Items]
Convertible Note Payable	$52,500

Notes_Payable_Summary_of_Notes1

Notes Payable - Summary of Notes Payable (Details) (Parenthetical) (USD $)	3 Months Ended	12 Months Ended
	Jan. 31, 2015	Oct. 31, 2014
Net of accumulated amortization	89,820	71,863
Convertible Notes Payable, Due May 23, 2015 [Member]
Convertible Note Payable, maturity date	23-May-15	23-May-15
Convertible Note Payable, Due June 23, 2015 [Member]
Convertible Note Payable, maturity date	23-Jun-15	23-Jun-15
Convertible Note Payable, Due October 22, 2015 [Member]
Convertible Note Payable, maturity date	22-Oct-15	22-Oct-15
Convertible Note Payable, due November 12, 2015 [Member]
Convertible Note Payable, maturity date	12-Nov-15
Convertible IBC Funds, LLC Payable, due November 21, 2015 [Member]
Convertible Note Payable, maturity date	21-Nov-15
Convertible Note Payable, due December 15, 2015 [Member]
Convertible Note Payable, maturity date	15-Dec-15
Convertible Note Payable, Due February 20, 2015 [Member]
Convertible Note Payable, maturity date		20-Feb-15

Derivative_Liabilities_Details

Derivative Liabilities (Details Narrative) (USD $)	3 Months Ended
	Jan. 31, 2015	Nov. 19, 2012
DerivativeLiabilitiesLineItems [Line Items]
Derivative liabilities	$647,729
Loss on change in fair value of derivative liability	$652,348
Conversion price per share		$0.23
Fair value assumptions, risk free interest rate	0.11%
Fair value assumptions, expected term	1 year
Fair value assumptions, expected dividend rate	0.00%
Minimum [Member]
DerivativeLiabilitiesLineItems [Line Items]
Conversion price per share	$0.02
Fair value assumptions, expected volatility rate	223.00%
Maximum [Member]
DerivativeLiabilitiesLineItems [Line Items]
Conversion price per share	$0.03
Fair value assumptions, expected volatility rate	342.00%

Fair_Value_Measurements_Schedu

Fair Value Measurements - Schedule of Fair Value of Liabilities Measured on Recurring Basis (Details) (USD $)	3 Months Ended
	Jan. 31, 2015	Oct. 31, 2014
Derivative liability on notes payable	$647,729	$201,260
Total Increase (Reduction) in Fair Value Recorded	652,348
Quoted Prices In Active Markets For Identical Assets Or Liabilities (Level 1) [Member]
Derivative liability on notes payable
Significant Other Observable Inputs (Level 2) [Member]
Derivative liability on notes payable
Significant Unobservable Inputs (Level 3) [Member]
Derivative liability on notes payable	$647,729

Fair_Value_Measurements_Schedu1

Fair Value Measurements - Schedule of Changes in Fair Value of Financial Liabilities or Derivative Liabilities (Details) (USD $)	3 Months Ended
	Jan. 31, 2015	Jan. 31, 2014
Fair Value Disclosures [Abstract]
Balance at beginning of period	$201,260	$99,702
Additions to derivative instruments	179,820
Change in fair value of derivative liabilities	652,348	-22,646
Settlements	-385,699	-18,400
Balance at end of period	$647,729	$58,656

Debentures_Payable_Details_Nar

Debentures Payable (Details Narrative) (USD $)	1 Months Ended			0 Months Ended
	Jun. 30, 2013	31-May-13	Feb. 28, 2013	Sep. 17, 2014	Nov. 19, 2012
Short-term Debt [Line Items]
Conversion price per share					$0.23
Warrant [Member]
Short-term Debt [Line Items]
Debt instrument term	3 years	3 years	3 years
Conversion price per share	$0.15	$0.15	$0.25
Series A Convertible Debenture [Member]
Short-term Debt [Line Items]
Debt instrument, interest rate terms			10.00%
Debt instrument term			3 years
Conversion price per share			$0.25
Debt Instrument, Redemption, Description			The warrants entitle the holder to purchase 2 times the number of common shares of the Company’s stock allowed in conjunction with the debentures at any time up to three years.
Series B Convertible Debenture [Member]
Short-term Debt [Line Items]
Debt instrument, interest rate terms	10.00%	10.00%
Debt instrument term	3 years	3 years
Conversion price per share	$0.25	$0.25
Debt Instrument, Redemption, Description	The warrants entitle the holder to purchase 1.5 times the number of common shares of the Company’s stock allowed in conjunction with the debentures at a price of $0.15 at any time up to three years	The warrants entitle the holder to purchase 1.5 times the number of common shares of the Company’s stock allowed in conjunction with the debentures at a price of $0.15 at any time up to three years
Series A and Series B Convertible Debentures [Member]
Short-term Debt [Line Items]
Debt converted to common stock shares				9,427,576

StockBased_Compensation_Detail

Stock-Based Compensation (Details Narrative) (USD $)	3 Months Ended
	Jan. 31, 2015	Jan. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-based employee compensation related to stock options	$0	$0

StockBased_Compensation_Summar

Stock-Based Compensation - Summary of Common Stock Options Granted, Forfeited or Expired and Exercised Under Plan (Details) (USD $)	3 Months Ended	12 Months Ended
	Jan. 31, 2015	Oct. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Options, Outstanding beginning balance	30,000	30,000
Options, Granted
Options, Forfeited/Expired
Options, Exercised
Options, Outstanding ending balance	30,000	30,000
Weighted Average Exercise price, Beginning balance	$0.90	$0.90
Weighted Average Exercise price, Granted
Weighted Average Exercise price, Forfeited/Expired
Weighted Average Exercise price, Exercised
Weighted Average Exercise price, Ending balance	$0.90	$0.90

Warrants_Schedule_of_Warrants_

Warrants - Schedule of Warrants Outstanding (Details)	Jan. 31, 2015	Oct. 31, 2014
Class of Warrant or Right [Line Items]
Warrants outstanding	8,457,500	8,457,500
Issued To Flow Capital Advisors Inc. On Settlement Of Lawsuit In August 2011, Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $0.30 Per Common Share Up To And Including August 23, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	250,000	250,000
Issued To Flow Capital Advisors Inc. On Settlement Of Lawsuit August 2011, Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $0.50 Per Common Share Up To And Including August 23, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	250,000	250,000
Issued To Flow Capital Advisors Inc. On Settlement Of Lawsuit August 2011, Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $0.75 Per Common Share Up To And Including August 23, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	500,000	500,000
Issued To Flow Capital Advisors Inc. On Settlement Of Lawsuit August 2011, Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $1.00 Per Common Share Up To And Including August 23, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	500,000	500,000
Issued To Flow Capital Advisors Inc. On Settlement Of Lawsuit August 2011, Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $0.75 Per Common Share Up To And Including August 23, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	500,000	500,000
Issued To Debenture Holders February 2013 Entitling The Holders To Purchase 1 Common Share In The Company At An Exercise Price Of $0.25 Per Common Share Up To And Including February 27, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	600,000	600,000
Issued To Debenture Holders May 2013 Entitling The Holders To Purchase 1 Common Share In The Company At An Exercise Price Of $0.15 Per Common Share Up To And Including June 3, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	750,000	750,000
Issued To Debenture Holders June 2013 Entitling The Holders To Purchase 1 Common Share In The Company At An Exercise Price Of $0.15 Per Common Share Up To And Including June 3, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	232,500	232,500
Issued To Consultants In August 5, 2013 Entitling The Holders To Purchase 1 Common Share In The Company At An Exercise Price Of $0.15 Per Common Share Up To And Including August 4, 2023 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	2,500,000	2,500,000
Issued To Consultants In August 5, 2013 Entitling The Holders To Purchase 1 Common Share In The Company At An Exercise Price Of $0.10 Per Common Share Up To And Including August 4, 2023 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	1,500,000	1,500,000
Issued To Consultant In September 3, 2013 Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $0.50 Per Common Share Up To And Including July 31, 2018 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	500,000	500,000
Issued To Shareholder October 29, 2013 Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $0.15 Per Common Share Up To And Including October 29, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	250,000	250,000
Issued To Shareholder November 7, 2013 Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $0.15 Per Common Share Up To And Including November 7, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	125,000	125,000

Warrants_Schedule_of_Warrants_1

Warrants - Schedule of Warrants Outstanding (Details) (Parenthetical) (USD $)	3 Months Ended	12 Months Ended
	Jan. 31, 2015	Oct. 31, 2014
Issued To Flow Capital Advisors Inc. On Settlement Of Lawsuit In August 2011, Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $0.30 Per Common Share Up To And Including August 23, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrant, exchange ratio to common stock	1	1
Warrants, exercise price	$0.30	$0.30
Warrant, last exercisable date	23-Aug-16	23-Aug-16
Issued To Flow Capital Advisors Inc. On Settlement Of Lawsuit August 2011, Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $0.50 Per Common Share Up To And Including August 23, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrant, exchange ratio to common stock	1	1
Warrants, exercise price	$0.50	$0.50
Warrant, last exercisable date	23-Aug-16	23-Aug-16
Issued To Flow Capital Advisors Inc. On Settlement Of Lawsuit August 2011, Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $0.75 Per Common Share Up To And Including August 23, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrant, exchange ratio to common stock	1	1
Warrants, exercise price	$0.75	$0.75
Warrant, last exercisable date	23-Aug-16	23-Aug-16
Issued To Flow Capital Advisors Inc. On Settlement Of Lawsuit August 2011, Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $1.00 Per Common Share Up To And Including August 23, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrant, exchange ratio to common stock	1	1
Warrants, exercise price	$1	$1
Warrant, last exercisable date	23-Aug-16	23-Aug-16
Issued To Flow Capital Advisors Inc. On Settlement Of Lawsuit August 2011, Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $0.75 Per Common Share Up To And Including August 23, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrant, exchange ratio to common stock	1	1
Warrants, exercise price	$0.75	$0.75
Warrant, last exercisable date	23-Aug-16	23-Aug-16
Issued To Debenture Holders February 2013 Entitling The Holders To Purchase 1 Common Share In The Company At An Exercise Price Of $0.25 Per Common Share Up To And Including February 27, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrant, exchange ratio to common stock	1	1
Warrants, exercise price	$0.25	$0.25
Warrant, last exercisable date	27-Feb-16	27-Feb-16
Issued To Debenture Holders May 2013 Entitling The Holders To Purchase 1 Common Share In The Company At An Exercise Price Of $0.15 Per Common Share Up To And Including June 3, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrant, exchange ratio to common stock	1	1
Warrants, exercise price	$0.15	$0.15
Warrant, last exercisable date	3-Jun-16	3-Jun-16
Issued To Debenture Holders June 2013 Entitling The Holders To Purchase 1 Common Share In The Company At An Exercise Price Of $0.15 Per Common Share Up To And Including June 3, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrant, exchange ratio to common stock	1	1
Warrants, exercise price	$0.15	$0.15
Warrant, last exercisable date	3-Jun-16	3-Jun-16
Issued To Consultants In August 5, 2013 Entitling The Holders To Purchase 1 Common Share In The Company At An Exercise Price Of $0.15 Per Common Share Up To And Including August 4, 2023 [Member]
Class of Warrant or Right [Line Items]
Warrant, exchange ratio to common stock	1	1
Warrants, exercise price	$0.15	$0.15
Warrant, last exercisable date	4-Aug-23	4-Aug-23
Issued To Consultants In August 5, 2013 Entitling The Holders To Purchase 1 Common Share In The Company At An Exercise Price Of $0.10 Per Common Share Up To And Including August 4, 2023 [Member]
Class of Warrant or Right [Line Items]
Warrant, exchange ratio to common stock	1	1
Warrants, exercise price	$0.10	$0.10
Warrant, last exercisable date	4-Aug-23	4-Aug-23
Issued To Consultant In September 3, 2013 Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $0.50 Per Common Share Up To And Including July 31, 2018 [Member]
Class of Warrant or Right [Line Items]
Warrant, exchange ratio to common stock	1	1
Warrants, exercise price	$0.50	$0.50
Warrant, last exercisable date	31-Jul-18	31-Jul-18
Issued To Shareholder October 29, 2013 Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $0.15 Per Common Share Up To And Including October 29, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrant, exchange ratio to common stock	1	1
Warrants, exercise price	$0.15	$0.15
Warrant, last exercisable date	29-Oct-16	29-Oct-16
Issued To Shareholder November 7, 2013 Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $0.15 Per Common Share Up To And Including November 7, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrant, exchange ratio to common stock	1	1
Warrants, exercise price	$0.15	$0.15
Issued to shareholder November 7, 2013, entitling the holder to purchase 1 common shares in the Company at an exercise price of $0.15 per common share up to and including November 7, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrant, last exercisable date	7-Nov-16	7-Nov-16

Issuance_of_Common_Stock_Detai

Issuance of Common Stock (Details Narrative) (USD $)	Jan. 31, 2015	Oct. 31, 2014	Jan. 17, 2013
Common stock shares, authorized	150,000,000	150,000,000
Preferred stock shares, authorized	50,000,000	50,000,000
Common stock, par value	$0.00	$0.00	$0.00
Minimum [Member]
Common stock shares, authorized			65,000,000
Preferred stock shares, authorized			5,000,000
Maximum [Member]
Common stock shares, authorized			150,000,000
Preferred stock shares, authorized			50,000,000

Issuance_of_Common_Stock_Sched

Issuance of Common Stock - Schedule of Common Stock Issue (Details)	3 Months Ended
	Jan. 31, 2015
Equity [Abstract]
Issued on conversion of notes payable	10,917,218

Net_Loss_per_Share_Details_Nar

Net Loss per Share (Details Narrative)	3 Months Ended
	Jan. 31, 2015	Jan. 31, 2014
Earnings Per Share [Abstract]
Incremental shares excluded from computation of diluted earning per share	29,074,285	12,725,418

Net_Loss_per_Share_Computation

Net Loss per Share - Computation of Weighted Average Shares Outstanding for Calculating Basic and Diluted Earnings Per Share (Details)	3 Months Ended
	Jan. 31, 2015	Jan. 31, 2014
Earnings Per Share [Abstract]
Weighted-average shares - basic	74,095,036	59,401,454
Effect of dilutive securities
Weighted-average shares - diluted	74,095,036	59,401,454

Supplemental_Disclosure_of_Cas2

Supplemental Disclosure of Cash Flow Information - Cash Flow Supplemental Disclosures (Details) (USD $)	3 Months Ended
	Jan. 31, 2015	Jan. 31, 2014
Supplemental Cash Flow Elements [Abstract]
Cash paid during the period for: Interest	$6,334	$3,856
Cash paid during the period for: Income taxes
Conversion of notes payable	137,921	12,066
Settlement of derivative liability	385,699	18,400
Issuance of shares on settlement of suit		$189,000

Subsequent_Events_Details_Narr

Subsequent Events (Details Narrative) (USD $)	3 Months Ended		0 Months Ended	1 Months Ended
	Jan. 31, 2015	Jan. 31, 2014	Dec. 15, 2014	Feb. 28, 2015
Debt conversion amount	$137,921	$12,066
LG Capital Funding, LLC [Member]
Convertible note payable			52,500
Note payable bearing interest rate			8.00%
Note payable due term			15 days
Subsequent Event [Member] | Officer [Member]
Issuance of common stock exchange for loans				22,856
Issuance of common stock shares exchange for loan				227,273
Subsequent Event [Member] | Consultant [Member]
Issuance of common stock for services, shares				100,000
Subsequent Event [Member] | LG Capital Funding, LLC [Member]
Debt conversion amount				10,561
Conversion of notes payable into common stock				1,456,703
Subsequent Event [Member] | LG Capital Funding, LLC [Member] | March 2015 [Member]
Debt conversion amount	10,072
Conversion of notes payable into common stock	1,039,913
Subsequent Event [Member] | Adar Bays, LLC [Member]
Debt conversion amount				21,700
Conversion of notes payable into common stock				3,227,706
Subsequent Event [Member] | Actus Private Equity [Member] | March 2015 [Member]
Convertible note payable	$55,250
Note payable bearing interest rate	8.00%
Note payable due term	1 year
Percentage of discount for common stock	40.00%